Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:33 a.m.

    📋 PROMETHEUS BIOSCIENCES, INC. (RXDX) - Clinical Trial Update

    Filing Date: 2022-06-08

    Accepted: 2022-06-08 09:01:03

    Event Type: Clinical Trial Update

    Event Details:

    Prometheus Biosciences Inc (company is now a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) (RXDX) Announces Clinical Trial Update Prometheus Biosciences Inc (company is now a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) (RXDX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Registrant
      • expected in the third quarter of this year. Topline results from both APOLLO-CD and the initial cohort of ARTEMIS-UC are expected in the fourth quarter of this year. Topline results from the Company’s Phase 2 trial of PRA023 in Systemic Sclerosis-Associated Interstitial Lung Disease, ATHENA-SSc-ILD, are expected in the first half of 2024

    🔬 Clinical Development Pipeline (PROMETHEUS BIOSCIENCES, INC.):

    Product Type Development Stage Therapeutic Area Source
    fenfluramine DRUG Phase PHASE3 Dravet Syndrome ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Prometheus Biosciences Inc (company is now a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada)
    • CIK: 0001718852
    • Ticker Symbol: RXDX
    • Period End Date: 2022-06-08
    • Document Type: 8-K

Search

News categories